Indian stocks: Visit www.stage2stocks.com →

BeOne Medicines Ltd.

Stage 2 · Advancing · week 9

As of Oct 22, 2026, BeOne Medicines is in Stage 2, the uptrend phase, now in week 9 (since Aug 25, 2026). It closed at $382.27, 1.7% below its 52-week high and above its 200-day average, which is rising.

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. More about the company

$382.27
-1.71% today
$43.5B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

—

Momentum

Steady

Edge

—

Setup-score rank among Stage 2 peers: #1 of 110 in Biotechnology · #1 of 272 in Health Care

Is ONC early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 17w
S2 15w
S2 14w
S2 25w
S4 15w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S4 4w → S1 3w → S4 12w → S1 3w → S4 17w → S1 1w → S4 4w → S1 5w → S4 2w → S1 2w → S2 15w → S3 8w → S2 14w → S3 6w → S2 25w → S3 4w → S2 9w → S3 3w → S4 15w → S1 4w → S2 8w current
Total tracked: 164 weeks across 21 stage runs.

ONC among Biotechnology134th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…134ONCStage 2 · wk 971+4.7%
vs 52W High
-1.7%
$260.27 lo$388.91 hi
Near 52W high
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 9
1w13w26w
Week 9, early Stage 2
How long this stock has been in Stage 2. The sweet spot is mid-run: long enough to prove the structure holds, not so long that it's extended. Very fresh moves (weeks 1–4) often need more time to confirm.
vs 200 DMA
18.0%
200 DMA: $323.89 · rising
Long-term trend anchor. When the stock and the S&P 500 are both above their 200-day averages, the backdrop supports continuation.
Rel Volume
0.95x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↗
Short-term trend rising gently
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+4.7%
3M
+17.3%
6M
+27.5%
YTD
+22.9%
1Y
+21.1%
Scan Membership
Breakout Watch
Latest: 2025-06-24
11 appearances in last 60 days. First seen: 2019-08-30.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S2
Wk 9 · Vol 0.95x
2026-10-21S2
Wk 9 · Vol 1.38x
2026-10-20S2
Wk 8 · Vol 1.05x
2026-10-19S2
Wk 8 · Vol 0.73x
2026-10-16S2
Wk 8 · Vol 1.10x
2026-10-15S2
Wk 8 · Vol 1.93x
2026-10-14S2
Wk 8 · Vol 0.93x
2026-10-13S2
Wk 7 · Vol 0.74x
2026-10-12S2
Wk 7 · Vol 0.67x
2026-10-09S2
Wk 7 · Vol 0.82x
2026-10-08S2
Wk 7 · Vol 1.10x
2026-10-07S2
Wk 7 · Vol 0.39x
Moving averages & range
50 DMA
$362.22
200 DMA
$323.89
52W High
$388.91
52W Low
$260.27
5D Low
$369.06
Resistance levels (recent highs)
20d High
$388.91
60d High
$388.91
120d High
$388.91
250d High
$388.91
Next resistance
+1.7%
to 20d High
P/E (TTM)
68.4
Forward 36.6
Earnings Growth (YoY)
+166.7%
Revenue +29.6%
ROE
+14.7%
Profit margin +10.7%
Dividend Yield
0.00%
P/B 8.4

BeOne Medicines: quick answers

What stage is BeOne Medicines in?

As of Oct 22, 2026, BeOne Medicines (ONC) is in Stage 2, the uptrend phase. It entered Stage 2 on Aug 25, 2026 and is in week 9. What the four stages mean

Is BeOne Medicines in an uptrend?

Yes. BeOne Medicines is in a Stage 2 uptrend. It trades 18.0% above its 200-day average, which is rising.

How far is BeOne Medicines from its 52-week high?

BeOne Medicines closed at $382.27 on Oct 22, 2026, 1.7% below its 52-week high of $388.91. Its 52-week low is $260.27.

How has BeOne Medicines performed over the past year?

As of Oct 22, 2026, BeOne Medicines is up 21.1% over the past year and up 22.9% so far in 2026.

Which sector and industry is BeOne Medicines in?

BeOne Medicines is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. The company has a agreement with U.S. government to expand access to innovative cancer medicines. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.